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Abstract
For current pandemic influenza H1N1, vaccine production started in the early summer,
and vaccination started in the fall. In most countries, by the time vaccination started, the
second wave of H1N1 was already under way. With limited supplies of vaccine, it might
be a good strategy to vaccinate the high-transmission groups earlier in the epidemic, but
it might be a better use of resources to protect instead the high-risk groups later on. We
develop a deterministic epidemic model with two age-groups (children and adults) and
further subdivide each age group in low and high risk. We compare optimal vaccination
strategies started at various points in time in two different settings: a population in the
United States (US) where children account for 24% of the population, and a population
in Senegal, where children make up for the majority of the population, 55%. For each of
these populations, we minimize mortality and we find an optimal vaccination vector that
gives us the best vaccine allocation given a starting vaccination date and vaccine coverage
level. We find that there is a switch in the optimal vaccination strategy at some time point
just before the peak of the epidemic. For instance, with 25% vaccine coverage, it is better
to protect the high-transmission groups before this point, but it is optimal to protect the
most vulnerable groups afterward.
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Introduction
For the current H1N1 influenza epidemic, vaccine production started in the early summer.
Several countries immediately ordered vaccine [9, 27], with the hope that the first pro-
duction batches would be ready in the early fall. This was not the case, however, and for
most countries vaccine arrived much later than predicted. Meanwhile, WHO expected to
supply 95 low- and middle-income countries with enough vaccine to cover 10% of their
populations [30]. When vaccine supplies are limited, vaccinating the high-transmission
groups, such as school children or young adults, has proven to be a good strategy for pre-
venting the spread of the disease, and by doing so the groups at high risk will be indirectly
protected [15, 11, 21, 24]. While this strategy makes sense earlier in the epidemic, this
might not be the optimal use of vaccine once the epidemic has begun. Indeed, once there is
a large proportion of the high-transmission groups infected and later on immune, vaccine
would probably have little effect in these groups and could be more effectively used in the
high-risk groups, giving them direct protection. Furthermore, the optimal use of vaccines
depends on the structure of the population: countries or cities where school children or
college students make up large proportions of the population will have different epidemic
dynamics than a country where these younger people make up a smaller proportion of the
population. We developed a deterministic model with two groups: children and adults,
and we further divided each of these age groups into low and high risk. We compared
optimal vaccination strategies in two different settings: a population in a developed coun-
try, United States (US), where the children make up for 24% of the population [26], and
a population in a developing country, Senegal, where the children account for 55% of the
population [23]. For each of these, we minimize mortality and we find an optimal vacci-
nation vector that gives us the best vaccine allocation given a starting vaccination date and
a given supply of vaccine.
Methods
Mathematical Model
Our model for influenza is based on the SIR model. We considered a closed population
of size N . Since influenza has a very short time scale compared to immigration or de-
mographics, none of these features are included. We divided the population into two sub-
populations of children and adults of size N1 and N2, so that N = N1 +N2. Furthermore,
within each sub-population, we divide members into high risk and low risk. Members in
each group are either susceptible, infected asymptomatic, infected symptomatic or recov-
ered and immune afterward. In addition, people can be either vaccinated or unvaccinated.
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The susceptibles are denoted by Slij , and Shij; infectious asymptomatic by Alij and Ahij;
infectious symptomatic by Ilij and Ihij; recovered asymptomatic by RAi, and recovered
symptomatic by Rli and Rhi where i = 1, 2 denotes the age group (children and adults,
respectively), j denotes the vaccination status (j = 0 for the unvaccinated and j = 1 for
the vaccinated), l denotes the low risk group and h denotes the high risk group.
The following assumptions were made.
• A fraction ρ of the infected people will never develop symptoms but will still trans-
mit the infection to others. Asymptomatic infected people have their infectiousness
reduced by a factor m compared to symptomatic infected people, where m ∈ [0, 1].
• cij represents the number of contacts per day between people in age group i and
people in age group j, where i, j = 1, 2.
• p is the probability of infection given contact. It will be used here as a parameter to
vary the severity of the infection.
• People are infectious as soon as they get infected, and they will stay infectious for
an average of 1/γ time units, where γ is the recovery rate.
• Following the ideas in [10], we consider that vaccination has three major effects:
(i) VES, the vaccine efficacy for susceptibility, is the ability of the vaccine to pre-
vent infection.
(ii) VEI, the vaccine efficacy for infectiousness, is the effect of the vaccine in re-
ducing infectiousness and transmission to others.
(iii) VEP, the vaccine efficacy for pathogenicity, accounts for the effect of the vac-
cine in reducing the symptoms given infection.
• The effect of each of the efficacies builds monotonically in time according to expontial-
like functions. Based on previous immunogenicity studies ([17, 18, 22, 20] for ex-
ample), we assumed that on average, the vaccine would reach its full potential 14
days after it was administered and would remain constant afterward for the period
being modeled.
This gives rise to the following system:
3
Hosted by The Berkeley Electronic Press
Equations for susceptibles
Unvaccinated Vaccinated
dSl10
dt
= −λ1Sl10 dSl11
dt
= −λ1θSl11 (1)
dSh10
dt
= −λ1Sh10 dSh11
dt
= −λ1θSh11 (2)
dSl20
dt
= −λ2Sl20 dSl21
dt
= −λ2θSl21 (3)
dSh20
dt
= −λ2Sl20 dSh21
dt
= −λ2θSl21 (4)
Equations for infected asymptomatics
Unvaccinated Vaccinated
dAl10
dt
= λ1(1− ρ)Sl10 − γAl10 dAl11
dt
= λ1(1− ρψ)θSl11 − γAl11 (5)
dAh10
dt
= λ1(1− ρ)Sh10 − γAh10 dAh11
dt
= λ1(1− ρψ)θSh11 − γAh11 (6)
dAl20
dt
= λ2(1− ρ)Sl20 − γAl20 dAl21
dt
= −λ2(1− ρψ)θSl21 − γAl21 (7)
dAh20
dt
= λ2(1− ρ)Sh20 − γAh20 dAh21
dt
= λ2(1− ρψ)θSh21 − γAh21 (8)
Equations for infected symptomatics
Unvaccinated Vaccinated
dIl10
dt
= λ1ρSl10 − γIl10 dIl11
dt
= λ1ρψθSl11 − γIl11 (9)
dIh10
dt
= λ1ρSh10 − γIh10 dIh11
dt
= λ1ρψθSh11 − γIh11 (10)
dIl20
dt
= λ2ρSl20 − γIl20 dIl21
dt
= λ2ρψθSl21 − γIl21 (11)
dIh20
dt
= λ2ρSh20 − γIh20 dIh21
dt
= λ2ρψθSh21 − γIh21 (12)
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Equations for the recovered
dRA1
dt
= γ(Al10 + Al11 + Ah10 + Ah11) (13)
dRA2
dt
= γ(Al20 + Al21 + Ah20 + Ah21) (14)
dRIl1
dt
= γ(Il10 + Il11) (15)
dRIh1
dt
= γ(Ih10 + Ih11) (16)
dRIl2
dt
= γ(Il20 + Il21) (17)
dRIh2
dt
= γ(Ih20 + Ih21) (18)
with forces of infection given by
λ1 =
pc11
N1
(
m(Al10 + Ah10) +mφ(Al11 + Ah11) + Il10 + Ih10 + φ(Il11 + Ih11)
)
+
pc12
N2
(
m(Al20 + Ah20) +mφ(Al21 + Ah21) + Il20 + Ih20 + φ(Il21 + Ih21)
)
,
and
λ2 =
pc21
N1
(
m(Al10 + Ah10) +mφ(Al11 + Ah11) + Il10 + Ih10 + φ(Il11 + Ih11)
)
+
pc22
N2
(
m(Al20 + Ah20) +mφ(Al21 + Ah21) + Il20 + Ih20 + φ(Il21 + Ih21)
)
.
We calibrated this model to the current H1N1 epidemic using the numbers given in
table 1 to obtain the final illness attack rates (defined as the percentage of the population
that became ill) shown in table 2. Based on current estimates, [8, 31, 1], we considered
the basic reproduction number R0 in the range [1.2, 1.8]. The basic reproduction numbers
were computed following the the approach given in [6] and [28, 4]. For the optimization,
the basic reproduction number was set to 1.6.
The different vaccination coverages considered were 2%, 15% and 25% of the popula-
tion. Vaccination could start on days one, 20, 40, 60, 80, and 100 days after the beginning
of infection transmission. For simplicity, we assumed that all the vaccine is delivered at
once, however, vaccinated people acquire their protection gradually as the vaccine effica-
cies build up over time.
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Our objective function g(fl1, fh1, fl2, fh2) was defined as follows
g(fl1, fh1, fl2, fh2) = 0.000031 ·RIl1 + 0.000416 ·RIh1+ (19)
0.000101 ·RIl1 + 0.000821 ·RIh2
(the dependence in the vaccination fractions in each group is not apparent since it is em-
bedded in the initial conditions of the system 1-18). This function represents the expected
number of deaths in each subgroup (children low and high risk, adults low and high risk)
and was computed as a weighted average with weights defined in table 1. Thus, we ob-
tained the optimization problem
min
(fl1,fh1,fl2,fh2)
g(fl1, fh1, fl2, fh2)
subject to the constraints
0 ≤ fl1, fh1, fl2, fh2 ≤ 1
fl1(1− 0.089)N1+fh10.089N1 + fl2(1− 0.212)N2 + fh20.212N2 = T
where T denotes the total number of doses available.
No influenza mortality or high risk data is available for Senegal, so we assumed that
both the proportions of people at high risk and the mortality rates for influenza A(H1N1)
for each group in Senegal were the same as the ones in the US. For each of the dates above,
and for each of the coverages given, we used an optimization package to determine a vector
(fl1, fh1, fl2, fh2) which corresponds to the optimal vaccine distribution for minimizing the
total number of deaths. Thus, the vector (fl1, fh1, fl2, fh2) gives us the fractions fl1 and
fh1 of children at low and high risk, and the fractions fl2 and fh2 of adults at low and high
risk respectively that would minimize mortality during the entire epidemic.
Results
Results for United States
The baseline epidemic curves for both US (blue) and Senegal (red) are plotted in figure
1 for a basic reproduction number of 1.6. Both countries have similar epidemic curves in
that there is no substantial spread before day 60, and the exponential phase of the epidemic
starts around day 45. The peak for Senegal occurs slightly earlier than for the US.
Figures 2 - 4 summarize the results for the US population. For each vaccination cov-
erage, the figures show the optimal vaccine allocation if vaccination were to start one, 20,
6
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Figure 1: Baseline epidemic curves for the US and Senegal for a basic reproduction num-
ber of 1.6
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Parameter Description Value Reference
γ recovery rate 0.25 [12]
ρ fraction of symptomatic 2/3 [12]
m reduction of infectiousness for asymptomatics 0.5 [12]
c11, c12, c21, c22 contact rates 1,0.2, 0.2, 0.4 calculateda
VES,VEI,VEP vaccine efficacies for susceptibility, infectiousness 0.4, 0.45, 0.75 [3]
and pathogenicity
N total population 200 000 assumption
initially infected fraction of the population 1/N assumption
percentage of children under 18 (US) 24.16 [26]
percentage of children under 19 (Senegal) 55 [23]
percentage of children at high risk 8.9 [19]
percentage of adults at high risk 21.2 [19]
mortality in low risk children 0.000031 [5]b
mortality in high risk children 0.000416 [5]
mortality in low risk adults 0.000101 [5]
mortality in high risk adults 0.000821 [5]
Table 1: Parameter values.
aThe contact rates were calculated to obtain the final illness attack rates shown in table 2.
bThe mortality rates in the last four rows were computed by weighting the estimates of deaths given in
[5] by the percentages of people in each subgroup given in [19].
40, 60, 80, or 100 days after the beginning of transmission. When there is enough vaccine
to cover only two percent of the US population, the best strategy is to allocate all the vac-
cine to the high-risk children (93% coverage) regardless of when vaccination begins (see
figure 2).
When supplies are large enough to vaccinate 15% of the population (figure 3), the
optimal strategy is to vaccinate all of the high-risk children and then to concentrate the
remainder of the vaccine in low-risk children, provided that vaccination occurs before the
peak. However, after the peak, it is optimal to cover all high-risk children and to switch
the remaining vaccine to high-risk adults (this accounts for 80% coverage in this group).
For instance, if vaccination were to start 20 days after the beginning of transmission, it
would be optimal to give vaccine to all the children at high risk (100% coverage in this
group) and to allocate the rest in the children at low risk (58% coverage in this group), but
if vaccination were to start 80 days after the beginning of transmission, then it would be
optimal to still vaccinate all the high-risk children and to vaccinate a fraction of the adults
8
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R0 Overall illness attack rate Illness attack rate in children Illness attack rate in adults
1 0 0 0
1.2 8.1 11.6 3.9
1.3 19.9 27.4 10.6
1.4 26.7 35.9 15.5
1.5 31 40.8 19
1.6 34.6 44.8 22.1
1.7 37.9 48.3 25.3
1.8 40.6 50.9 28
Table 2: Final illness attack rates for the range of basic reproduction numbers considered.
high-risk (80% coverage in this group).
Figure 4 presents the results for the US when enough vaccine is available to cover 25%
of the population. Assuming that vaccination occurred before the exponential phase of the
epidemic, vaccinating all of the high-risk children and then concentrating the remainder
of the vaccine in low-risk children (90% coverage in this group) is the optimal solution,
but this time a small amount of vaccine can be given to high-risk adults (19% coverage
in high risk adults). In contrast, if vaccination takes place during or after the exponential
phase, then it is optimal to favor first all of the high-risk children and all high-risk adults,
and then to concentrate the remainder of supplies in low-risk children (30% coverage in
low-risk children).
In general, with limited supplies of vaccine, it is always optimal to concentrate vaccine
in high-risk children to provide them with direct protection, as they are part of the high-
transmission chain and they are among the most vulnerable. As vaccine supplies increases,
it becomes optimal to allocate the resources in the high-transmission group; in our model,
children at low-risk. This makes sense since by protecting the high-transmission group,
we stop the chain of transmission and indirectly protect the high risk groups. However,
this policy is optimal only up to a certain time during or after the exponential rise phase,
when too many high-transmission people have already been infected and have acquired
natural immunity. After this point in time, it is optimal to concentrate vaccine in high-risk
groups protecting them directly.
9
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Results for Senegal
Figures 5 - 7 give the analogous results for Senegal as to those in the US. In this scenario,
children make up a much larger proportion (55%) than they do in the US (24%). Here, if
coverage is very low, (two percent of the population) and vaccination were to occur before
exponential phase, it is optimal to concentrate all the available vaccine in high-risk chil-
dren (41% coverage); whereas if vaccination were to occur during or after the exponential
phase, it is optimal to shift vaccine coverage to high-risk adults (21% coverage), see figure
5.
When there is enough vaccine for 15% of the population, then, regardless of the phase
of the epidemic, it is optimal to protect both the high-risk groups, children and adults, and
to allocate the remainder of supplies in low-risk children (1% coverage in this group), see
figure 6. This is due to the fact that with this coverage, we would not be able to block
transmission by protecting the high-transmission groups, so it is better to directly protect
all the members of the most vulnerable groups, and by doing so the number of deaths are
greatly diminish.
Interestingly, this policy is no longer optimal with 25% coverage. In this situation,
there is again a shift in the optimal policy depending on the time of vaccination relative to
the peak: if vaccination occurs before the exponential phase, it is optimal to concentrate
it in children (100% of the high-risk children and 40% of the low-risk). But when vacci-
nation occurs later on, the optimal strategy shifts to the high-risk groups, (100% coverage
of both children and adults at high-risk) with allocation of the remainder of the vaccine
to low-risk children (21% coverage in this group). This makes sense, because according
to our model, by allocating this much vaccine in children earlier on in the epidemic, we
would be able to block transmission and mitigate the disease, but if vaccination took place
later on in the epidemic, there are too many people already infected and this strategy is no
longer useful (see figure 8).
In this scenario, the optimal solution is to concentrate vaccine in the high-risk groups.
Indeed, for low supplies of vaccine, it is optimal to concentrate vaccine in high-risk chil-
dren before the peak and in high risk adults after the peak. As more vaccine becomes
available, it is optimal to allocate it to the high risk groups until there is enough vaccine
to fully cover this groups. However, once we have supplies to cover a significant fraction
(around 40%) of the high-transmission group, then it is optimal to vaccinate this group
before the peak of the epidemic as this will greatly reduce transmission.
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Optimal vaccination strategy with 2% coverage, United States
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Figure 2: Optimal vaccination policy when there is enough vaccine to cover 2% of the
population in United States starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Optimal vaccination strategy with 15% coverage, United States
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Figure 3: Optimal vaccination policy when there is enough vaccine to cover 15% of the
population in United States starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Optimal vaccination strategy with 25% coverage, United States
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Figure 4: Optimal vaccination policy when there is enough vaccine to cover 25% of the
population in United States starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Optimal vaccination strategy with 2% coverage, Senegal
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Figure 5: Optimal vaccination policy when there is enough vaccine to cover 2% of the
population in Senegal starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Optimal vaccination strategy with 15% coverage, Senegal
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Figure 6: Optimal vaccination policy when there is enough vaccine to cover 15% of the
population in Senegal starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Optimal vaccination strategy with 25% coverage, Senegal
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Figure 7: Optimal vaccination policy when there is enough vaccine to cover 25% of the
population in Senegal starting one, 20, 40, 60, 80, or 100 days after the beginning of
transmission. The epidemic curve for the symptomatic infections is shown in black.
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Figure 8: Epidemic curve for Senegal with 25% of the population coverage. The vaccine
has been administered to children at high-risk (100% coverage of this group) and children
at low risk (40% coverage of this group) starting 20 days (red curve) or 80 days (blue
curve) after the beginning of transmission. This strategy is optimal before the exponential
rise of the epidemic and controls the outbreak but it is suboptimal after it.
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Discussion
We use a mathematical model to find the optimal vaccine allocation at different time points
of an epidemic. For both developed and developing countries, when faced with low sup-
plies of vaccines, it is better to allocate vaccine to the high risk groups. For developed
countries, as more vaccine becomes available, it is optimal to allocate vaccine to high-
transmission groups earlier in the epidemic, but to concentrate in high-risk groups during
or after the exponential phase of the epidemic. In contrast, for developing countries, it
is better to allocate vaccine in the high-risk groups first and then cover high-transmission
groups. Once vaccine supplies reach a certain coverage level, then it becomes important to
vaccinate the high-transmission groups in the earlier stages of the epidemic, but this policy
becomes suboptimal once the peak of the epidemic has passed. These results highlight two
important features: first, the population structure is extremely important. For a country like
Senegal, where the high-transmission group accounts for the majority of the population,
one needs large amounts of vaccine to indirectly protect the high-risk groups by vacci-
nating the high-transmission ones. However, in a country like the US, where high-risk
groups represent a smaller fraction of the population, it is possible to reduce transmission
by vaccinating the high-transmission groups, if this is done early in the epidemic. The
second important point is that timing of the vaccination is extremely important and greatly
determines where the efforts should be concentrated.
The optimal results presented here are sensitive to the population structure, both in the
percentages of each group and subgroup and in the contact pattern among them. Given the
uncertainty of these parameters for pandemic influenza A(H1N1), we agree with Dushoff
et al. [7] that one should be cautious in interpreting the results offered by simple models.
Here, the only difference considered between US and Senegal is the proportion of children
and adults in each country. While this is a key factor, there are many other important fea-
tures that make these countries different and would give rise to different optimal solutions.
For instance, it could be important to incorporate more detailed data for Senegal including
influenza-related case fatality ratios, the composition and percentages of high-risk groups,
and vaccine availability and distribution patterns. Senegal has a higher infant and child
mortality rate than the US, so one could imagine that the fraction of children at high risk
in Senegal will be greater than in the US. Moreover, differences in the health system in
both countries might be a crucial factor in minimizing the number of deaths. Adding more
groups to the populations will make a more realistic model. Finally, one could expect very
different results if the objective function was different, such as final illness attack rates,
remaining years of life lost, hospitalizations, economic burden or a combination of these.
Previous work [2, 13, 25] has suggested that in presence of low vaccine supplies, high-
risk groups should be prioritized but high-transmission groups should be vaccinated with
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larger quantities of vaccine. Our results agree with this strategy for a population with a
structure similar to the one in the US as long as vaccination starts before the peak of the
epidemic. However, we suggest that there is a threshold in the time when a switch in the
optimal strategy occurs, after which, the resources will be more useful if allocated directly
to the high-risk groups. This is in agreement with the results found by others [14, 16, 29].
The particular time for this threshold is strongly dependent on the values of the model
parameters, in particular on the vaccination coverage and the structure of the population,
but in general, occurs some time during the exponential phase of the epidemic or right at
the peak.
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